Intech Investment Management LLC Grows Holdings in Amgen Inc. $AMGN

Key Points

• Intech Investment Management LLC increased its Amgen stake by 9.4% in the fourth quarter, ending with 52,904 shares valued at about $17.3 million.
• Amgen reported strong quarterly results, with EPS of $5.15 beating estimates and revenue of $8.62 billion, up 5.8% year over year.
• The company announced a quarterly dividend of $2.52 per share, implying a 3.0% annualized yield, while analysts currently rate the stock a consensus Hold with a $355.19 target price.

Intech Investment Management LLC raised its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 9.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 52,904 shares of the medical research company's stock after buying an additional 4,540 shares during the period. Intech Investment Management LLC's holdings in Amgen were worth $17,316,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of AMGN. Dogwood Wealth Management LLC grew its holdings in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock valued at $25,000 after acquiring an additional 55 shares in the last quarter. Anfield Capital Management LLC lifted its holdings in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock worth $25,000 after acquiring an additional 70 shares during the period. Board of the Pension Protection Fund purchased a new position in Amgen in the fourth quarter worth $26,000. Manning & Napier Advisors LLC grew its stake in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock valued at $32,000 after purchasing an additional 32 shares during the period. Finally, Olistico Wealth LLC bought a new position in Amgen in the 4th quarter valued at $33,000. Institutional investors own 76.50% of the company's stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company's stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.85% of the company's stock.

Amgen Trading Up 0.1%

Shares of AMGN stock opened at $336.48 on Friday. The stock has a market capitalization of $181.60 billion, a price-to-earnings ratio of 23.42, a PEG ratio of 3.37 and a beta of 0.44. The company's fifty day simple moving average is $342.83 and its two-hundred day simple moving average is $345.39. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period last year, the company earned $4.90 earnings per share. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. Amgen's dividend payout ratio is currently 70.15%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on AMGN shares. Mizuho lifted their target price on Amgen from $280.00 to $295.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 10th. Guggenheim decreased their price objective on shares of Amgen from $351.00 to $340.00 and set a "neutral" rating for the company in a report on Monday, May 4th. Wells Fargo & Company lifted their price objective on shares of Amgen from $375.00 to $390.00 and gave the stock an "equal weight" rating in a research report on Thursday, March 19th. Rothschild & Co Redburn boosted their target price on shares of Amgen from $180.00 to $200.00 and gave the company a "sell" rating in a research note on Wednesday, February 18th. Finally, Oppenheimer set a $400.00 target price on shares of Amgen and gave the company an "outperform" rating in a research report on Thursday, January 29th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $355.19.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.